多巴胺联合硝普钠治疗心肌梗死后左心衰竭的效果分析

Analysis of the Effect of Dopamine Combined with Sodium Nitroprusside in the Treatment of Left Heart Failure after Myocardial Infarction

摘要:

〔摘 要〕 目的： 探讨多巴胺联合硝普钠治疗心肌梗死后左心衰竭的临床效果。方法： 从 2017 年 6 月至 2020 年 5 月期 间河南科技大学第一附属医院诊治的心肌梗死后左心衰竭患者中随机抽取 90 例作为研究对象，按照治疗方法不同对患者 分组，对照组和观察组均为 45 例。对照组采用常规治疗，观察组在常规治疗基础上增加多巴胺＋硝普钠方案治疗，比较 两组患者的临床疗效。结果： 观察组患者的治疗总有效率为 95.56 %，明显高于对照组的 77.78 %，差异具有统计学意义 （P ＜ 0.05）。治疗前，两组患者的临床症状、体征相关指标比较，差异无统计学意义（P ＞ 0.05）；治疗后，两组患者的 相关指标均明显改善，且观察组较对照组改善更加明显，差异均具有统计学意义（P ＜ 0.05）。结论： 对心肌梗死后左心 衰竭患者采用多巴胺＋硝普钠方案治疗，具有较好的效果。

Abstract:

〔Abstract〕Objective To explore the clinical effect of dopamine combined with sodium nitroprusside in the treatment of left heart failure after myocardial infarction. Methods From June 2017 to May 2020, 90 patients with left heart failure after myocardial infarction diagnosed and treated in the First Affiliated Hospital of Henan University of Science and Technology were randomly selected as the research objects, and the patients were divided into two groups according to different treatment methods, the control group and the observation, with 45 cases in each group. The control group received conventional treatment, and the observation group added dopamine combined with sodium nitroprusside treatment on the basis of conventional treatment. The clinical efficacy of the two groups of patients was compared. Results The total effective rate of treatment in the observation group was 95.56%, which was significantly higher than 77.78% in the control group. The difference was statistically significant (P < 0.05). Before treatment, there was no statistically significant difference in the clinical symptoms and signs of the two groups of patients (P > 0.05); after treatment, the related indicators of the two groups of patients were significantly improved, and the observation group improved more significantly than the control group. The differences were all statistically significant (P < 0.05). Conclusion The therapy of dopamine combined with sodium nitroprusside is effective for patients with left heart failure after myocardial infarction.